| Name | Title | Contact Details |
|---|
Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our TAILWINDTM Platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing and clinical application. Catamaran is backed by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures and Astellas Venture Management.
Verax Biomedical Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Interface Biologics Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Exagen Diagnostics Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Inhibitex, Inc. is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.